The San Diego, CA-based biotechnology company is focused on the development of novel, broad-spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections.
The company today announced the completion of an $85m Series A financing round led by existing investors Sinopharm Healthcare Fund and Lilly Asia Ventures.
New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment.
The funds will be used to support a Phase III clinical trial of Ansun’s experimental anti-viral medication, DAS181, which was granted Fast Track status and Breakthrough therapy designation by the US Food and Drug Administration (FDA).
DAS181 is a potentially first-in-class therapeutic that can be used to treat respiratory viral infections, according to the company. The Phase II clinical trial was completed last year.